Pure Global
NCT05912205

Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation

An Open, Single Arm, Phase II Clinical Study on the Efficacy and Safety of Bladder Sparing Therapy With Vidixizumab Combined With Local Radiotherapy in Patients With HER-2 Expressing Myometrial Invasive Urothelium Carcinoma
Wuhan Union Hospital, China·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Urothelial Carcinoma
Drug/Device/Intervention
Disitamab Vedotin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Wuhan Union Hospital, China
Timeline & enrollment
Phase
Phase 2
Start date
Jul 01, 2023
End date
Jul 01, 2026
Enrollment
30 participants
Primary outcome

Bladder-intact event-free survival

Summary

This is a prospective, open, single center clinical study of vidicizumab combined with local
 radiotherapy as bladder conserving therapy in patients with muscle invasive bladder
 urothelium cancer with HER-2 expression (IHC 2+or 3+). A total of 30 subjects were included
 in the study

ICD-10 classifications
Carcinoma in situ: Other and unspecified urinary organsMalignant neoplasm of ureterMalignant neoplasms of urinary tractMalignant neoplasm: Overlapping lesion of urinary organsMalignant neoplasm: Urethra
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05912205
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05912205 through Pure Global AI's free database. This Phase 2 trial is sponsored by Wuhan Union Hospital, China and is currently Not yet recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.